Advances in researches on neoadjuvant therapy for resectable colorectal liver metastasis.
10.3760/cma.j.cn.441530-20200213-00053
- Author:
Ting Yue GONG
1
;
Min Hao YU
1
;
Ming ZHONG
1
Author Information
1. Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
- Publication Type:Review
- Keywords:
Circulating tumor DNA(ctDNA);
Colorectal neoplasms;
Initially resectable;
Liver metastasis;
Neoadjuvant therapy
- MeSH:
Colorectal Neoplasms/surgery*;
Hepatectomy;
Humans;
Liver Neoplasms/surgery*;
Neoadjuvant Therapy;
Neoplasm Recurrence, Local/surgery*
- From:
Chinese Journal of Gastrointestinal Surgery
2021;24(3):279-282
- CountryChina
- Language:Chinese
-
Abstract:
Surgery is recognized as the core treatment for colorectal liver metastasis (CRLM), while its recurrence rate remains relatively high, even for resectable CRLM. This hints that the efficacy of treatment involves not only technological factors of surgery, but also biological behavior of tumor. For resectable CRLM, neoadjuvant therapy is beneficial to eliminate the micro-metastasis, reduce postoperative recurrence rate, screen tumor biological behavior and improve prognosis. However, questions about which kind of CRLM patients fits for neoadjuvant therapy and what regimen should be used are still debatable. This paper reviews stratified management of resectable CRLM, choice of neoadjuvant regimen, especially the application value of targeted therapy, based on the latest guidelines and studies.
